CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Sees Significant Decline in Short Interest

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 414,235 shares, a decline of 14.2% from the March 15th total of 483,060 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 128,124 shares, the short-interest ratio is presently 3.2 days.

CAMP4 Therapeutics Trading Up 2.1%

NASDAQ CAMP traded up $0.10 during trading hours on Friday, hitting $4.69. 6,117 shares of the company’s stock traded hands, compared to its average volume of 178,360. CAMP4 Therapeutics has a 52 week low of $1.30 and a 52 week high of $7.75. The firm has a market capitalization of $243.25 million, a P/E ratio of -1.82 and a beta of 0.41. The business’s fifty day moving average price is $4.63 and its two-hundred day moving average price is $4.50.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, March 5th. The Wireless communications provider reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.56). The company had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 162.49% and a negative net margin of 2,298.54%. On average, sell-side analysts expect that CAMP4 Therapeutics will post -4.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on CAMP. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of CAMP4 Therapeutics in a report on Monday, December 29th. Leerink Partners raised their price target on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.60.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in CAMP4 Therapeutics during the 4th quarter worth approximately $157,000. Janus Henderson Group PLC boosted its position in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after purchasing an additional 1,666,666 shares during the period. Vivo Capital LLC purchased a new stake in shares of CAMP4 Therapeutics in the third quarter worth $11,765,000. Geode Capital Management LLC raised its position in shares of CAMP4 Therapeutics by 457.0% during the 4th quarter. Geode Capital Management LLC now owns 336,293 shares of the Wireless communications provider’s stock valued at $2,063,000 after purchasing an additional 275,922 shares during the period. Finally, 683 Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at $775,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.